These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27630127)

  • 1. A Three-Drug Combo for Multiple Myeloma.
    Cancer Discov; 2016 Nov; 6(11):OF4. PubMed ID: 27630127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
    N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
    Elsada A; Adler AI
    Lancet Oncol; 2019 May; 20(5):619-620. PubMed ID: 30981602
    [No Abstract]   [Full Text] [Related]  

  • 5. Daratumumab plus bortezomib and dexamethasone
    Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
    Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
    Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
    Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Daratumumab for multiple myeloma].
    Croizier C; Bailly S
    Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
    Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
    Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
    Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
    Ozaki S; Hata H; Abe M; Saitoh T; Hanamura I; Yano H; Sunami K; Kosugi H; Sawamura M; Nakazato T; Masunari T; Mori M; Takagi T; Murakami H; Shimizu K
    Ann Hematol; 2016 May; 95(6):921-9. PubMed ID: 27044390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
    Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
    Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
    Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.
    Arcuri LJ; Americo AD
    Ann Hematol; 2021 Mar; 100(3):725-734. PubMed ID: 33432438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
    Ahn JS; Jung SH; Lee SS; Ahn SY; Yang DH; Kim YK; Kim HJ; Lee JJ
    Biomed Res Int; 2014; 2014():145843. PubMed ID: 25530955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
    Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gunawardena S; Lutska Y; Qi K; Ukropec J; Qi M; Lin TS; Rifkin RM
    Br J Haematol; 2019 May; 185(3):492-502. PubMed ID: 30828799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Aparecida Martinez G; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV;
    N Engl J Med; 2024 Aug; 391(5):393-407. PubMed ID: 38828933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
    Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
    Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Blair HA
    Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
    Pan D; Kaufman JL; Htut M; Agrawal M; Mazumder A; Cornell RF; Zonder JA; Fay JW; Modiano MR; Moshier EL; Rush SA; Tunquist BJ; Chari A
    Cancer Med; 2022 Jan; 11(2):358-370. PubMed ID: 34921527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.